氟伐他汀药物基因组学的研究进展  

Research Progress on the Pharmacogenomics of Fluvastatin

作　　者：严同[1] YAN Tong(Center for Obesity and Metabolic Diseases,The Third People's Hospital of Chengdu,Chengdu Sichuan 610031,China)

机构地区：[1]成都市第三人民医院肥胖与代谢性疾病中心,成都610031

出　　处：《药品评价》2020年第21期3-5,共3页Drug Evaluation

摘　　要：氟伐他汀是一种3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂,用于治疗高胆固醇血症。氟伐他汀主要通过CYP2C9进行代谢。此外,氟伐他汀还是几种药物转运蛋白的底物,包括有机阴离子转运多肽、钠依赖性牛磺胆酸盐共转运多肽等。氟伐他汀的药代动力学存在较大的个体差异。本文将综述氟伐他汀药物基因组学的研究进展。Fluvastatin is a 3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase inhibitor,which is used in the treatment of hypercholesterolemia.Fluvastatin is extensively metabolized via CYP2C9.In addition,Fluvastatin is a substrate of several drug transporters,including organic anion transporting polypeptides and sodium‐dependent taurocholate cotransporting polypeptide.High interindividual variability exists in the pharmacokinetics of fluvastatin.This review summarizes the research progress on the pharmacokinetics of fluvastatin.

关 键 词：氟伐他汀 CYP2C9 OATP1B1 基因组学 药代动力学 

分 类 号：R972+.6[医药卫生—药品]